S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
Log in

Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS)

$62.53
-0.21 (-0.33 %)
(As of 10/14/2019 04:00 PM ET)
Today's Range
$62.26
Now: $62.53
$63.10
50-Day Range
$57.64
MA: $62.45
$68.67
52-Week Range
$44.52
Now: $62.53
$86.58
Volume476,737 shs
Average Volume1.15 million shs
Market Capitalization$8.79 billion
P/E Ratio21.13
Dividend YieldN/A
Beta1.95
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$599.67 million
Cash Flow$3.22 per share
Book Value$8.63 per share

Profitability

Net Income$273.74 million

Miscellaneous

Employees737
Market Cap$8.79 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.26. The company earned $164 million during the quarter, compared to analysts' expectations of $145.31 million. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. The firm's quarterly revenue was up 39.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.29) EPS. View Ionis Pharmaceuticals' Earnings History.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Ionis Pharmaceuticals.

What price target have analysts set for IONS?

10 equities research analysts have issued 1-year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $50.00 to $120.00. On average, they expect Ionis Pharmaceuticals' share price to reach $76.90 in the next twelve months. This suggests a possible upside of 22.9% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

What is the consensus analysts' recommendation for Ionis Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.

What are Wall Street analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (7/31/2019)
  • 2. Cantor Fitzgerald analysts commented, ". $68 PT. Biogen (BIIB, Young, Neutral) reported earnings this morning and discussed the outlook for Spinraza, which is a key product for Ionis (receives low-20s royalty). Incremental color suggests that the broader SMA market, especially ex-US, is likely much larger than initially expected. However, we see disruptive potential from competitors (risdiplam and gene therapy) which continues to leave us cautious on the long-term Spinraza opportunity. We are hosting a conference call on Monday at 10 AM ET to discuss our thoughts on the key SMA competitor updates expected at AAN (early May) and stock reads to IONS, BIIB and PTCT (Overweight, Young). Call details below." (4/24/2019)

Has Ionis Pharmaceuticals been receiving favorable news coverage?

News articles about IONS stock have trended negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a news impact score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Ionis Pharmaceuticals.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 10,510,000 shares, a decline of 6.7% from the August 30th total of 11,260,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is presently 10.1 days. Approximately 8.2% of the company's shares are short sold. View Ionis Pharmaceuticals' Current Options Chain.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), BlackRock (BLK), Micron Technology (MU), Alnylam Pharmaceuticals (ALNY), Gilead Sciences (GILD), Alibaba Group (BABA), Biogen (BIIB), Intercept Pharmaceuticals (ICPT), Allergan (AGN) and Celgene (CELG).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:
  • Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
  • Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
  • Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Decatur Capital Management Inc. (0.05%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Decatur Capital Management Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $62.58.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $8.79 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  553 (Vote Outperform)
Underperform Votes:  613 (Vote Underperform)
Total Votes:  1,166
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel